Caspofungin (INN) (brand name Cancidas worldwide) is a lipopeptide antifungal biologic from Merck & Co., Inc.. It is a associate of a new chichi of antifungals termed the echinocandins. It works by inhibiting the advocate β(1,3)-D-Glucan synthase and thereby advancing the artlessness of the fungal corpuscle wall. Caspofungin was the ancient inhibitor of fungal β-1,3 glucan admixture to be acclimatized by the United States Food and Biologic Administration. Caspofungin is administered intravenously.
Indications
Caspofungin acetate for blast was originally acclimatized by both the Food and Biologic Administration (FDA), in the US, and the EMEA, in Europe, in 2001. Its currently acclimatized ameliorative breach by both organisations awning the empiric assay of accustomed fungal infections in febrile, neutropenic developed patients and the assay of invasive aspergillosis in developed patients whose anguish is adverse to, or who are advancing of, added antifungal agents (i.e., accustomed or lipid formulations of amphotericin B and/or itraconazole). Additionally, the FDA approval includes adumbration for the assay of candidemia and some specific Candida infections (intra-abdominal abscesses, peritonitis, pleural atrium infections and oesophagitis) and the EMEA approval includes adumbration for the assay of accustomed invasive candidiasis in developed patients.
Read more:Caspofungin price